Clinical investigation of new medicinal products for the treatment of acute coronary syndrome

Current effective version

PDF iconAdopted guideline

Reference numberEMA/CHMP/760125/2016
Published20/09/2017
Effective from01/03/2018
KeywordsAcute coronary syndrome, STE-ACS, NSTE-ACS
DescriptionThis guideline replaces 'Points to consider on the clinical investigation of new medicinal products for the treatment of acute coronary syndrome (ACS) without persistent ST segment elevation' (CPMP/EWP/570/98) and 'Points to consider on the clinical development of fibrinolytic medicinal products in the treatment of patients with ST segment elevation acute myocardial infarction (STEMI)' (CPMP/EWP/967/01).


Document history

First version

Current version

PDF iconAdopted guideline

PDF iconOverview of comments


PDF iconDraft guideline

PDF iconConcept paper

In operation: 01/03/2018 - present

Published: 26/09/2017

Published: 27/04/2016

Published: 15/10/2014

Superseded document PDF iconAdopted guideline In operation: 01/09/2000 - 01/03/2018


Related content


How useful was this page?

Add your rating